The next D&T Committee meeting will be held May 8, 2019
HFS will be reviewing the following classes for the May meeting:
Antiasthmatic - Monoclonal Antibodies
Migraine Products - Monoclonal Antibodies
All clinical and financial submissions for this meeting must be sent to the Department no later than 3pm CST on April 17, 2019. Any changes to drug status will become effective on or after July 1, 2019.